Roche Holding AG (RHHBY)
| Market Cap | 333.01B +27.0% |
| Revenue (ttm) | 79.90B +1.5% |
| Net Income | 16.24B +55.6% |
| EPS | 20.23 +55.6% |
| Shares Out | n/a |
| PE Ratio | 20.50 |
| Forward PE | 15.94 |
| Dividend | 0.97 (1.91%) |
| Ex-Dividend Date | Mar 13, 2026 |
| Volume | 148,366 |
| Average Volume | 2,821,065 |
| Open | 51.81 |
| Previous Close | 51.10 |
| Day's Range | 51.62 - 52.38 |
| 52-Week Range | 37.51 - 60.85 |
| Beta | 0.33 |
| RSI | 56.06 |
| Earnings Date | Jul 23, 2026 |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavir... [Read more]
Financial Performance
In 2025, Roche Holding AG's revenue was 63.36 billion, an increase of 1.54% compared to the previous year's 62.40 billion. Earnings were 12.88 billion, an increase of 55.61%.
Financial numbers in CHF Financial StatementsNews
Genentech to Present New Data at ASCO 2026, Reinforcing Giredestrant's Potential to Transform the Treatment Paradigm in Early Breast Cancer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), will present new data from nine approved and investigational medicines across more th...
Roche to present new data at ASCO 2026, reinforcing giredestrant's potential to transform the treatment paradigm in early breast cancer
Basel, 19 May 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) will present new data from nine approved and investigational medicines across more than 15 indications at the 2026 American Society of Clinical ...
Roche, Medicines Patent Pool sign deal to expand access to influenza drug
Roche and the Medicines Patent Pool have signed a licensing agreement to expand access to the Swiss drugmaker's flu drug, Xofluza, in low- and middle-income countries, the organizations said on Monda...
FDA Approves Genentech's Tecentriq for Adjuvant Muscle-Invasive Bladder Cancer With ctDNA-Guided Treatment
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Tecentr...
Roche CEO Expects Pharma Portfolio to Deliver Sales Growth Through 2030
The drugmaker's on-market pharma portfolio, together with drugs for lupus, breast cancer and multiple sclerosis, should offset generic competition until 2030, Chief Executive Thomas Schinecker said.
Roche Holding AG Transcript: Roche Diagnostics Day 2026
The event outlined a strategy centered on innovation, digital integration, and targeted growth in high-burden disease areas. Key launches like AXELIOS sequencing and CGM are set to drive mid to high single-digit sales growth, with profit outpacing sales, supported by strategic acquisitions and a robust pipeline.
Roche Holding AG Slides: FY 2026
Roche Holding AG has posted slides in relation to its FY 2026 quarterly earnings report, which was published on May 12, 2026.
Roche gets second European approval for Alzheimer's test
Swiss drugmaker Roche has received the CE mark - a European regulatory clearance allowing sale in the region - for its second Elecsys blood test for Alzheimer's disease, it said on Tuesday.
Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)
Basel, 12 May 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that it has received CE Mark for Elecsys® pTau217, a blood test developed in collaboration with Eli Lilly and Company and design...
Roche to Buy PathAI for Up to $1.05 Billion to Bolster AI Diagnostics Tools
The deal seeks to bolster the artificial-intelligence offerings of Roche's diagnostics division, helping to accelerate clinical-therapy development.
Switzerland's Roche agrees to acquire US-based PathAI
Swiss pharmaceutical giant Roche said on Thursday it had agreed to acquire U.S.-based digital pathology and AI-powered technology firm PathAI in a deal worth $750 million upfront plus further miles...
Roche enters into a definitive merger agreement to acquire PathAI to transform AI-driven diagnostics
Basel, 7 May 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that it has entered into a definitive merger agreement to acquire PathAI, a US-based company in digital pathology and AI-powered...
Genentech to Present Extensive Data Showcasing Its Industry-Leading Ophthalmology Portfolio at ARVO 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that it will showcase key real-world, product and pipeline data from ...
Roche to present extensive data showcasing its industry-leading ophthalmology portfolio at ARVO 2026
Basel, 30 April 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that it will showcase key real-world, product and pipeline data from its ophthalmology portfolio at the Association for Resear...
Genentech Partners With Comedy Icon Damon Wayans and diaTribe to Address Diabetes-Related Vision Loss With ‘All Eyes on DME' Campaign
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced the launch of All Eyes on DME, a campaign developed in partnership with adv...
Roche Holding AG Earnings Call Transcript: Q1 2026
Sales grew 6% at constant exchange rates in Q1 2026, led by strong Pharma and Diagnostics performance, despite currency headwinds and China pricing reforms. Multiple regulatory filings and positive clinical data support a robust pipeline, with guidance for mid-single-digit sales and high single-digit EPS growth reaffirmed.
Roche Holding AG Slides: Q1 2026
Roche Holding AG has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 23, 2026.
Roche Holding AG Earnings release: Q1 2026
Roche Holding AG released its Q1 2026 earnings on April 23, 2026, summarizing the period's financial results.
Europe risks falling further behind in medicine race, warns Roche CEO
Europe risks falling further behind the United States and China in pharmaceutical research and innovation because of "mind-blowing" bureaucracy and government policies threatening jobs, Roche Chief E...
Roche CEO laments Swiss franc strength as drugmaker doubles down on U.S. investment
Roche sales fell 5% in the first quarter, but increased 6% in constant exchange rates. The appreciation of the Swiss franc against most currencies, notably the U.S. dollar, had a significant impact on...
Roche Backs Full-Year View as Quarterly Sales Rise
Roche confirmed its full-year guidance after reporting a first-quarter rise in sales driven by high demand for its innovative medicines and diagnostics.
Roche Q1 sales down on forex effects
Swiss drugmaker Roche said on Thursday that its first-quarter sales declined because of negative foreign exchange effects but rose at constant exchange rates.
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong sales growth of +6% at constant exchange rates in the first quarter of 2026; -5% in CHF due to the significant appreciation of the Swiss franc
Group sales were +6% at constant exchange rates (CER)1, -5% when reported in CHF and +9% in USD2, in the first three months, driven by high demand for our innovative medicines and diagnostics. Pharmac...
Roche Holding AG Transcript: Investor update
Fenebrutinib showed strong efficacy in reducing relapses and MRI disease activity in relapsing MS, with a favorable safety profile overall, though an imbalance in fatalities was noted without a clear mechanistic link. The drug is positioned for broad use across MS types, with regulatory filing planned mid-year.
Roche Holding AG Slides: Investor update
Roche Holding AG has posted slides in relation to its latest quarterly earnings report, which was published on April 22, 2026.